LONDON – Santhera Pharmaceuticals Holding AG is expanding its Duchenne muscular dystrophy (DMD) franchise in a deal to license rights to vamorolone, a new class of steroid drug designed to reduce side effects and allow for longer-term treatment than is possible with current glucocorticoid therapy.